Commentary|Videos|July 25, 2025
How the Mechanisms of KRAS(ON) Inhibitors Differ From KRAS(OFF) Inhibitors
Fact checked by: Chris Ryan
Mike J. Pishvaian, MD, PhD, and Martin Dietrich, MD, PhD, discuss how KRAS(ON) inhibitors differ in mechanism from KRAS(OFF) inhibitors.
Advertisement
Advertisement
Related to this article
The FDA has issued a CRL to LNTH-2501 for the localization of SSTR-positive NETs.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
China’s NMPA has satri-cel for pretreated, CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
GLP-1 Receptor Agonists, Endocrine Therapy, and Metabolic Health Comprise Holistic Breast Cancer Care
3
Dr Geyer on the FDA Approval of T-DXd Followed by THP for HER2+ Breast Cancer
4
SYNC-T SV-102 Employs Novel Mechanism to Target Immunologically ‘Cold’ Tumors in Advanced Metastatic Prostate Cancer
5